Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Meningococcal Disease Vaccine Market from 2024 to 2025?

Over recent years, the market size for the meningococcal disease vaccine has experienced swift growth. It is projected to increase from $2.37 billion in 2024 to reach $2.62 billion in 2025, indicating a compound annual growth rate (CAGR) of 10.4%. This growth during the historical period can be credited to factors like enhanced vaccine production capacity, global healthcare collaborations, incorporation in national immunization schedules, an increase in cases of meningococcal disease, and growing initiatives by organizations.

What Is the Projected Market Size of the Meningococcal Disease Vaccine Market?

In the forthcoming years, a swift expansion is anticipated in the meningococcal disease vaccine market. The market is projected to achieve a volume of $3.83 billion by 2029, growing at a compound annual growth rate (CAGR) of 10.0%. The surge in the forecast period is credited to rising cognizance of proactive healthcare, broadening target demographic, fresh participants entering the market, governmental and health agency accumulation in anticipation of possible outbreaks, and heightened public awareness. Upcoming trends for this period comprise of advancements in vaccine technology, manufacturing of multivalent, conjugate, and protein-based vaccines, universal travel and migration patterns, an escalation in research and development for mRNA, and breakthroughs in thermostable formulations.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24317&type=smp

Who are the Major Competitors in the Meningococcal Disease Vaccine Market Outlook?

Major companies operating in the meningococcal disease vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, Novartis AG, GlaxoSmithKline plc, Hualan Biological Engineering Inc., Beijing Tiantan Biological Products Corporation Limited, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co. Ltd., Incepta Pharmaceuticals Ltd., CanSino Biologics Inc., EuBiologics Co. Ltd., Biovac Institute, Shantha Biotech, Bio-Manguinhos, Biomed Pvt. Ltd., Chengdu Kanghua Biological Products Co. Ltd., Zhejiang Tianyuan Bio-Pharmaceutical Co. Ltd., Finlay Institute of Vaccines, Immunopreparat.

What Is Fueling Growth in the Meningococcal Disease Vaccine Market?

The escalation in government-led immunization initiatives is perceived to bolster the progress of the meningococcal disease vaccine market. Such initiatives are crucial health strategies that supply free or inexpensive vaccines to guard communities against communicable diseases. Due to an increased focus on thwarting infectious diseases and reducing healthcare pressure through extensive vaccinations, these initiatives are on the rise. They influence the growth of meningococcal vaccines by widening access and boosting vaccination rates, alongside improving awareness and decreasing disease cases. They also generate demand by making vaccinations obligatory and advocating public health. For example, in April 2024, the Pan American Health Organization (PAHO), a specialized agency based in the United States, inaugurated the 22nd Vaccination Week in the Americas (VWA) under the theme Engage now to protect your future. GetVax. The aim was to enhance vaccination coverage, particularly in underserved regions, by delivering over 65 million doses and combating misinformation while improving access to vaccines through community participation and customized campaigns. Thus, the growth of the meningococcal disease vaccine market is being fuelled by the rise in government immunization programs.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24317&type=smp

Which Meningococcal Disease Vaccine Market Segments Are Growing the Fastest?

The meningococcal disease vaccine market covered in this report is segmented –

1) By Vaccine Type: Conjugate Vaccines, Polysaccharide Vaccines, Recombinant Vaccines, Live Attenuated Vaccines

2) By Age Group: Infants, Children, Adults, Older Adults

3) By Indication: Preventive Vaccination, Post-Exposure Prophylaxis, Travel-Related Vaccination, Outbreak Response

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Conjugate Vaccines: Monovalent Conjugate Vaccines, Quadrivalent Conjugate Vaccines, Pediatric Conjugate Vaccines, Adolescent Or Adult Conjugate Vaccines

2) By Polysaccharide Vaccines: Bivalent Polysaccharide Vaccines, Trivalent Polysaccharide Vaccines, Quadrivalent Polysaccharide Vaccines, Age-Specific Polysaccharide Formulations

3) By Recombinant Vaccines: Serogroup B Recombinant Protein Vaccines, Multicomponent Recombinant Vaccines, Outer Membrane Vesicle (OMV) Based Recombinant Vaccines

4) By Live Attenuated Vaccines: Experimental Intranasal Live Attenuated Vaccines, Genetically Engineered Attenuated Strain Vaccines, Combined Live Attenuated Vaccines

Which Industry Trends Are Shaping the Future of the Meningococcal Disease Vaccine Market?

The main players in the meningococcal disease vaccine market are focusing their efforts on advancing product development, such as the creation of pentavalent meningococcal vaccines. These vaccines will increase serogroup coverage, streamline immunization timings, and bolster disease prevention efforts. A pentavalent meningococcal vaccine is an innovative immunization method that targets five major Neisseria meningitidis serogroups in just one dose, negating the requirement for several distinct vaccines and enhancing adherence. In October 2023, Pfizer Inc., a pharmaceutical corporation based in the United States, announced the approval of its new vaccine, PENBRAYA, by the Food and Drug Administration (FDA). PENBRAYA, designed for preventing meningococcal disease in individuals between 10 and 25 years old, is the first and only of its kind, combining components from Trumenba and Nimenrix, two existing meningococcal vaccines. It offers protection against the five most common serogroups (A, B, C, W, and Y) of Neisseria meningitidis, which are responsible for the majority of invasive meningococcal disease (IMD) cases worldwide. PENBRAYA illustrates a substantial progression in meningococcal disease prevention as it provides broader serogroup coverage than any other available meningococcal vaccine in the U.S., and could simplify the vaccination process by reducing the overall number of doses necessary for complete protection.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/meningococcal-disease-vaccine-global-market-report

Which Countries Are Leading the Meningococcal Disease Vaccine Market?

North America was the largest region in the meningococcal disease vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the meningococcal disease vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/customise?id=24317&type=smp

This Report Delivers Insight On:

1. How big is the meningococcal disease vaccine market, and how is it changing globally?

2. Who are the major companies in the meningococcal disease vaccine market, and how are they performing?

3. What are the key opportunities and risks in the meningococcal disease vaccine market right now?

4. Which products or customer segments are growing the most in the meningococcal disease vaccine market?

5. What factors are helping or slowing down the growth of the meningococcal disease vaccine market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model